Gastrointestinal Stromal Tumors

Conference Insider
Ripretinib Yields Clinical Benefit; Proven Tolerability in Advanced GIST
06/17/2021
INVICTUS study results reveal intra-patient dose escalation (IPDE) of ripretinib after disease progression indicate clinical benefit and tolerability in patients with advanced gastrointestinal stromal tumors.
INVICTUS study results reveal intra-patient dose escalation (IPDE) of ripretinib after disease progression indicate clinical benefit and tolerability in patients with advanced gastrointestinal stromal tumors.
INVICTUS study results reveal...
06/17/2021
Oncology
Conference Insider
Experts Investigate Value of Chromosomal Complexity in Imatinib Treatment for High-Risk GIST
06/17/2021
Investigators sought to determine if chromosomal complexity could be used as a biomarker in de-escalation of adjuvant imatinib treatment, presented at the 2021 ASCO Annual Meeting.
Investigators sought to determine if chromosomal complexity could be used as a biomarker in de-escalation of adjuvant imatinib treatment, presented at the 2021 ASCO Annual Meeting.
Investigators sought to...
06/17/2021
Oncology
Conference Insider
Pimitespib Significantly Improves PFS, OS in Patients with Advanced GIST
06/15/2021
A phase III trial evaluated the efficacy and safety of pimitesib in patients with advanced GIST refractory to standard treatments, whose medical requirements remain unmet, presented at the 2021 ASCO Annual Meeting.
A phase III trial evaluated the efficacy and safety of pimitesib in patients with advanced GIST refractory to standard treatments, whose medical requirements remain unmet, presented at the 2021 ASCO Annual Meeting.
A phase III trial evaluated the...
06/15/2021
Oncology
Conference Insider
Selinexor+Imatinib Combo Found Well Tolerated in IM-Resistant Advanced GIST
06/15/2021
Results following the phase Ib portion in the evaluation of imatinib in combination with selinexor displays well tolerability in patients with imatinib (IM)-resistant, advanced GIST, presented at the 2021 ASCO Annual Meeting.
Results following the phase Ib portion in the evaluation of imatinib in combination with selinexor displays well tolerability in patients with imatinib (IM)-resistant, advanced GIST, presented at the 2021 ASCO Annual Meeting.
Results following the phase Ib...
06/15/2021
Oncology
Dr Ilson Talks Current Role of Immunotherapy in GEJ, GI Cancer- Part I
Videos
Dr Ilson Talks Current Role of Immunotherapy in GEJ, GI Cancer- Part I
03/24/2021
In part 1 of this video series, David Ilson, MD, PhD, reviews recent immunotherapy updates in GEJ/gastric cancer.
In part 1 of this video series, David Ilson, MD, PhD, reviews recent immunotherapy updates in GEJ/gastric cancer.
In part 1 of this video series,...
03/24/2021
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use